The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
Open accessAbstract
Bone remodeling requires a precise balance between resorption and formation. It is a complex process that involves numerous factors: hormones, growth factors, vitamins, and cytokines, and notably osteoprotegerin (OPG) and receptor activator for nuclear factor-κB (RANK) ligand. The signaling pathway OPG/RANK/RANKL is key to regulation for maintaining the balance between the activity of osteoblasts and osteoclasts in order to prevent bone loss and ensure a normal bone turnover. In this review, the RANK/RANKL/OPG pathway is described. The multiple interactions of various factors (hormones, cytokines, growth factors, and vitamins) with the OPG/RANK/RANKL pathway are also commented on. Finally, the effects of denosumab, a human monoclonal antibody that binds to RANKL and thereby inhibits the activation of osteoclasts, and of strontium ranelate are also described. Indeed, these two new drugs afford appreciable assistance in daily care practice, helping to prevent bone loss in patients with osteoporosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · cited 1×
“Osteoclasts are derived from the hematopoietic lineage and differentiate in order to degrade bone.(1) The osteoclast precursor matures into a multinucleated cell and attaches itself to the bone surface, where it is attracted by different factors such as cytokines, hormones, and growth factor, and differentiates into a…”
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“7,8 RANK, the receptor of RANKL, as with OPG, is a receptor from the TNF family.”
Minireview: The OPG/RANKL/RANK System
Khosla, S. (2001) · Endocrinology · doi:10.1210/endo.142.12.8536 · Cited by 1,515
Denosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825 · cited 2×
“13 Studies on the effects of androgens have yielded conflicting results on their effects on OPG.”
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis
Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Yano, K., Morinaga, T., & Higashio, K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9788 · Cited by 746 · cited 1×
“9 In transgenic mice, knockout of either RANK or RANKL led to the same phenotypes, concluding that RANK and RANKL had very few roles apart from their interactions.”
Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Spelsberg, T. C., & Riggs, B. L. (1999) · Endocrinology · doi:10.1210/endo.140.9.7131 · Cited by 692 · cited 1×
“11,33,34 Studies involving postmenopausal women to determine a relationship between the menopause and an increase in OPG put forth different conclusions.”
Lee, S.-K., & Lorenzo, J. A. (1999) · Endocrinology · doi:10.1210/endo.140.8.6887 · Cited by 464
Ma, Y. L., Cain, R. L., Halladay, D. L., Yang, X., Zeng, Q., Miles, R. R., Chandrasekhar, S., Martin, T. J., & Onyia, J. E. (2001) · Endocrinology · doi:10.1210/endo.142.9.8356 · Cited by 428 · cited 1×
“19 Seck et al found conflicting results while analyzing the expression of OPG and RANKL in human bone tissue in vivo in women having surgery for breast cancer.”
Bord, S., Ireland, D. C., Beavan, S. R., & Compston, J. E. (2003) · Bone · doi:10.1016/s8756-3282(02)00953-5 · Cited by 333
Rogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215 · cited 1×
“OPG was the first protein of the pathway to be identified in 1997.(3) It was discovered in mice by sequencing random clones, and the full-length gene was proven to encode for a new tumor necrosis factor (TNF) receptor.”
Correlates of osteoprotegerin levels in women and men.
Khosla, S., Arrighi, H. M., Melton, III, Atkinson, E. J., O'Fallon, W. M., Dunstan, C., & Riggs, B. L. (2002) · Osteoporosis International · doi:10.1007/s001980200045 · Cited by 205 · cited 8×
“In a large cohort of Chinese patients with either an extremely high hip BMD or an extremely low hip BMD, men with TC/CC genotypes of the polymorphism rs9594782 of the RANKL gene ( TNFRSF11 A ) had a significantly higher risk of extremely low hip BMD and lower whole-body BMD.”
InfluentialMichael, H., Härkönen, P. L., Väänänen, H. K., & Hentunen, T. A. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050803 · Cited by 200
Rogers, A., Saleh, G., Hannon, R. A., Greenfield, D., & Eastell, R. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020396 · Cited by 200 · cited 2×
“In some studies, no association was found between BMD and OPG, 21,39,42,43 whereas other works demonstrated a significant inverse correlation between OPG and BMD, 44 notably in postmenopausal women without any hormone replacement therapy.”
Khosla, S., Atkinson, E. J., Dunstan, C. R., & O’Fallon, W. M. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8397 · Cited by 191 · cited 2×
“12 Furthermore, a negative association between OPG and PTH was found in men.”
Serum levels of osteoprotegerin increase with age in a healthy adult population.
Kudlacek, S., Schneider, B., Woloszczuk, W., Pietschmann, P., & Willvonseder, R. (2003) · Bone · doi:10.1016/s8756-3282(03)00090-5 · Cited by 187
Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover.
Indridason, O. S., Franzson, L., & Sigurdsson, G. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1699-x · Cited by 107
Mezquita-Raya, P., de la Higuera, M., García, D. F., Alonso, G., Ruiz-Requena, M. E., de Dios Luna, J., Escobar-Jiménez, F., & Muñoz-Torres, M. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1844-1 · Cited by 98 · cited 2×
“In several other cohorts, no correlation was found between OPG and bone resorption markers in women whatever their menopause status was.(36,40) In contrast, a positive relationship between bone turnover markers and OPG was found in postmenopausal women(41) and in both men and women in a study by Indridason et al.”
J�rgensen, H. L., Kusk, P., Madsen, B., Fenger, M., & Lauritzen, J. B. (2004) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-003-0461-3 · Cited by 85
Gannagé‐Yared, M., Fares, F., Semaan, M., Khalife, S., & Jambart, S. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02522.x · Cited by 76 · cited 1×
“45,50 In men 53 As in women, the correlation between OPG and sex steroids in men is very conflicting in the different publications.”
Oh, K. W., Rhee, E. J., Lee, W. Y., Kim, S. W., Baek, K. H., Kang, M. I., Yun, E. J., Park, C. Y., Ihm, S. H., Choi, M. G., et al. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02179.x · Cited by 73 · cited 9×
“Mezquita-Raya et al 36 (tALP, TRAP), Fahrleitner-Pammer et al, 41 Indridason et al 42 (OC), Liu et al 43 (urinary NTx) Nabipour et al, 32 Han et al, 37 Khosla et al 40 Rogers et al, 39 Indridason et al 42 (TRAP) BMD Nabipour et al, 32 Mezquita-Raya et al, 36 Chiba et al, 46 Stern et al 47 (women with HRT) Han et al, 3…”
InfluentialHofbauer, L., Hicok, K., Chen, D., & Khosla, S. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1470269 · Cited by 72
Roshandel, D., Holliday, K. L., Pye, S. R., Boonen, S., Borghs, H., Vanderschueren, D., Huhtaniemi, I. T., Adams, J. E., Ward, K. A., Bartfai, G., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.78 · Cited by 66 · cited 6×
“In a large cohort of Chinese patients with either an extremely high hip BMD or an extremely low hip BMD, men with TC/CC genotypes of the polymorphism rs9594782 of the RANKL gene ( TNFRSF11 A ) had a significantly higher risk of extremely low hip BMD and lower whole-body BMD.”
InfluentialFahrleitner-Pammer, A., Dobnig, H., Piswanger-Soelkner, C., Bonelli, C., Dimai, H.-P., Leb, G., & Obermayer-Pietsch, B. (2003) · Wiener Klinische Wochenschrift · doi:10.1007/bf03040334 · Cited by 62
Oh, E. S., Rhee, E.-J., Oh, K. W., Lee, W. Y., Baek, K. H., Yoon, K. H., Kang, M. I., Yun, E. J., Park, C. Y., Choi, M. G., et al. (2005) · Metabolism · doi:10.1016/j.metabol.2004.08.005 · Cited by 61
Nakamichi, Y., Udagawa, N., Kobayashi, Y., Nakamura, M., Yamamoto, Y., Yamashita, T., Mizoguchi, T., Sato, M., Mogi, M., Penninger, J. M., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.1.192 · Cited by 50 · cited 1×
“49 In a few studies that were conducted to determine the relationship between aging and RANKL in postmenopausal women, an increase of RANKL expression was described in post-menopausal women compared with premenopausal women and women using estrogen treatment.”
Han, K. O., Choi, J. T., Choi, H. A., Moon, I. G., Yim, C. H., Park, W. K., Yoon, H. K., & Han, I. K. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02221.x · Cited by 32 · cited 1×
“37 Dehydroepiandrosterone (DHEA) is another hormone linked to aging, and it is known to decrease with aging.”
Cited by
Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium
Mabbott, N. A., Donaldson, D. S., Ohno, H., Williams, I. R., & Mahajan, A. (2013) · Mucosal Immunology · doi:10.1038/mi.2013.30 · Cited by 721
Osteoprotegerin levels decrease in abstinent alcohol-dependent patients
Malik, P., von Gleissenthall, G., Gasser, R. W., Moncayo, R., Giesinger, J. M., & Mechtcheriakov, S. (2016) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13063 · Cited by 4
Metadata
- Authors
- Goëb, V., & Anne-Priscille, T.
- Venue
- Clinical Interventions in Aging
- Publisher
- Informa UK Limited
- Published
- 2010-11
- Volume
- 5
- Pages
- 345
- ISSN
- 1176-9092 (ISSN-L)
- 1178-1998
- OpenAlex
- W2020378019
- Cited by
- 179
- References
- 29
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.